Other News To Note
Wednesday, September 19, 2012
Critical Outcome Technologies Inc., of London, Ontario, said it started the final series of toxicity experiments in two animal species for lead oncology compound COTI-2, a small molecule designed to act by inhibiting Akt/protein kinase B phosphorylation. The completion of those experiments represents the final of three major risk reduction studies needed to make COTI-2 an investigational new drug application-ready compound.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.